Table 1.
Correlations between HPV status and different clinicopathologic characteristics
| Variable | Frequency (%) | ||||
|---|---|---|---|---|---|
| N | 143 | ||||
| HPV-driven | Non-HPV-driven | All | P value | ||
| Sex | Male | 86 (79) | 25 (71) | 111 | 0.312b |
| Female | 22 (21) | 10 (29) | 32 | ||
| Age (years) | Range | 39–87 | 34–82 | 34–87 | 0.066a |
| Mean | 58.5 | 62 | 59.5 | ||
| Stage TNM 7 | I | 2 (2) | 1 (3) | 3 | 0.666c |
| II | 4 (4) | 2 (6) | 6 | ||
| III | 12 (11) | 5 (14) | 17 | ||
| IV | 90 (83) | 27 (77) | 117 | ||
| Stage TNM 8 | I | 10 (9) | 1 (3) | 11 | < 0.001c* |
| II | 72 (67) | 6 (17) | 78 | ||
| III | 26 (24) | 8 (23) | 34 | ||
| IV | 0 | 20 (57) | 20 | ||
| Localization | Tonsillar cancer | 86 (79) | 15 (43) | 101 | < 0.001b* |
| Base of tongue cancer | 17 (16) | 14 (40) | 31 | ||
| Other oropharyngeal cancer | 5 (5) | 6 (17) | 11 | ||
| Differentiation grade | Low | 50 (48) | 7 (20) | 57 | 0.011b* |
| Moderate | 48 (46) | 22 (65) | 70 | ||
| High | 6 (6) | 5 (15) | 11 | ||
| NK | 4 | 1 | 5 | ||
| Smoking habit | Smoker | 58 (59) | 28 (85) | 86 | 0.007b* |
| Nonsmoker | 40 (41) | 5 (15) | 45 | ||
| NK | 10 | 2 | 12 | ||
| Recurrence | Yes | 19 (18) | 15 (43) | 34 | < 0.001b* |
| No | 82 (76) | 13 (37) | 95 | ||
| Residual tumor | 7 (6) | 7 (20) | 14 | ||
| Vital status | Alive | 74 (68) | 8 (23) | 82 | < 0.001b* |
| Dead | 34 (32) | 27 (77) | 61 | ||
| Cause of death | Cancer | 23 (72) | 24 (89) | 47 | 0.106b |
| Other | 9 (28) | 3 (11) | 12 | ||
| NK | 2 | - | 2 | ||
| LMO7 expression | Absent | 1 (1.5) | 1 (4) | 2 | 0.732c |
| 1–25% | 18 (25.5) | 5 (20) | 23 | ||
| 26–50% | 16 (22.5) | 7 (28) | 23 | ||
| 51–75% | 11 (15.5) | 5 (20) | 16 | ||
| 76–100% | 25 (35) | 7 (28) | 32 | ||
| NK | 37 | 10 | |||
| LMO7 intensity | No | 1 (2) | 1 (5) | 2 | 0.884c |
| Weak | 12 (21) | 4 (20) | 16 | ||
| Intermediate | 37 (65) | 13 (65) | 50 | ||
| Strong | 7 (12) | 2 (10) | 9 | ||
| NK | 51 | 15 | 66 | ||
| LRIG1 expression | Absent | 1 (1.5) | 0 | 1 | 1c |
| 1–25% | 0 | 0 | 0 | ||
| 26–50% | 2 (3) | 0 | 2 | ||
| 51–75% | 4 (6) | 1 (4) | 5 | ||
| 76–100% | 61 (89.5) | 25 (96) | 86 | ||
| NK | 40 | 9 | 49 | ||
| LRGI1 intensity | No | 1 (1.5) | 0 | 1 | 0.755c |
| Weak | 4 (6) | 0 | 4 | ||
| Intermediate | 54 (77) | 21 (81) | 75 | ||
| Strong | 11 (15.5) | 5 (19) | 16 | ||
| NK | 38 | 9 | 47 | ||
| CD44 expression | Absent | 9 (13) | 1 (4) | 10 | 0.048b* |
| 1–25% | 26 (37) | 3 (12) | 29 | ||
| 26–50% | 9 (13) | 4 (16) | 13 | ||
| 51–75% | 13 (18.5) | 7 (28) | 20 | ||
| 76–100% | 13 (18.5) | 10 (40) | 23 | ||
| NK | 38 | 10 | 48 | ||
| CD44 intensity | No | 9 (13) | 1 (4) | 10 | 0.024b* |
| Weak | 24 (34) | 5 (20) | 29 | ||
| Intermediate | 28 (40) | 9 (36) | 37 | ||
| Strong | 9 (13) | 10 (40) | 19 | ||
| NK | 38 | 10 | 48 | ||
| Ki67 expression | Mean | 56 | 43 | 52.5 | 0.06a |
| p53 expression | Wild-type | 70 (98.5) | 8 (31) | 78 | < 0.001b* |
| Mutated | 1 (1.5) | 18 (69) | 19 | ||
| NK | 37 | 9 | 46 | ||
HPV human papillomavirus, NK not known, LRIG leucine-rich repeats and immunoglobulin-like domain, LMO7 LIM domain 7 protein
aIndependent samples t-test
bChi2-test
cFisher’s exact test
* = P < 0.05